These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 39009356)

  • 1. Correction of omega-3 fatty acid deficiency and improvement in disease activity in patients with systemic lupus erythematosus treated with krill oil concentrate: a multicentre, randomised, double-blind, placebo-controlled trial.
    Salmon J; Wallace DJ; Rus V; Cox A; Dykas C; Williams B; Ding Y; Hals PA; Johnsen L; Lipsky PE
    Lupus Sci Med; 2024 Jul; 11(2):. PubMed ID: 39009356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus.
    Arriens C; Hynan LS; Lerman RH; Karp DR; Mohan C
    Nutr J; 2015 Aug; 14():82. PubMed ID: 26283629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus.
    Bello KJ; Fang H; Fazeli P; Bolad W; Corretti M; Magder LS; Petri M
    Rheumatol Int; 2013 Nov; 33(11):2789-96. PubMed ID: 23817872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Omega-3 fatty acid supplementation in systemic lupus erythematosus patients: A systematic review.
    Ramessar N; Borad A; Schlesinger N
    Lupus; 2022 Mar; 31(3):287-296. PubMed ID: 35023407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus.
    Wright SA; O'Prey FM; McHenry MT; Leahey WJ; Devine AB; Duffy EM; Johnston DG; Finch MB; Bell AL; McVeigh GE
    Ann Rheum Dis; 2008 Jun; 67(6):841-8. PubMed ID: 17875549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of melatonin supplementation on serum oxidative stress markers and disease activity in systemic lupus erythematosus patients: A randomised, double-blind, placebo-controlled trial.
    Nabatian-Asl M; Ghorbanihaghjo A; Malek Mahdavi A; Khabbazi A; Hajialilo M; Ghojazadeh M
    Int J Clin Pract; 2021 Jul; 75(7):e14246. PubMed ID: 33877728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Lima GL; Paupitz J; Aikawa NE; Takayama L; Bonfa E; Pereira RM
    Arthritis Care Res (Hoboken); 2016 Jan; 68(1):91-8. PubMed ID: 25988278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease.
    Deinema LA; Vingrys AJ; Wong CY; Jackson DC; Chinnery HR; Downie LE
    Ophthalmology; 2017 Jan; 124(1):43-52. PubMed ID: 27817918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
    Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B
    Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.
    Burge DJ; Werth VP; Boackle SA; Posada J
    Lupus Sci Med; 2024 Feb; 11(1):. PubMed ID: 38325898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.
    Mozaffarian D; Maki KC; Bays HE; Aguilera F; Gould G; Hegele RA; Moriarty PM; Robinson JG; Shi P; Tur JF; Lapointe JF; Aziz S; Lemieux P;
    JAMA Netw Open; 2022 Jan; 5(1):e2141898. PubMed ID: 34989797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
    Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA
    Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Krill oil improved osteoarthritic knee pain in adults with mild to moderate knee osteoarthritis: a 6-month multicenter, randomized, double-blind, placebo-controlled trial.
    Stonehouse W; Benassi-Evans B; Bednarz J; Vincent AD; Hall S; Hill CL
    Am J Clin Nutr; 2022 Sep; 116(3):672-685. PubMed ID: 35880828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
    Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial.
    Zimmer R; Scherbarth HR; Rillo OL; Gomez-Reino JJ; Muller S
    Ann Rheum Dis; 2013 Nov; 72(11):1830-5. PubMed ID: 23172751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
    Merrill JT; Shanahan WR; Scheinberg M; Kalunian KC; Wofsy D; Martin RS
    Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study.
    van Vollenhoven RF; Hahn BH; Tsokos GC; Lipsky P; Gordon RM; Fei K; Lo KH; Chevrier M; Rose S; Berry P; Yao Z; Karyekar CS; Zuraw Q
    J Rheumatol; 2022 Apr; 49(4):380-387. PubMed ID: 34853089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus.
    Duffy EM; Meenagh GK; McMillan SA; Strain JJ; Hannigan BM; Bell AL
    J Rheumatol; 2004 Aug; 31(8):1551-6. PubMed ID: 15290734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.